Merrimack Pharmaceuticals Inc
MACKDelisted May 10, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001274792
Merrimack Pharmaceuticals Inc was delisted on May 10, 2024; its insiders filed their last Form 4 on Dec 28, 2023; 70 institutions reported holding it in 13F filings for Q1 2024, worth $137.1M in total; no superinvestor held it.
Q3 2021 vs. Q2 2021
How the institutions holding Merrimack Pharmaceuticals Inc changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 42 | 38 | −4 |
| Shares | 7.87M | 7.68M | −194.2K (−2.5%) |
| Value | $50.3M | $37.1M | −$13.2M (−26.2%) |
New holders (2)
Institutions that held Merrimack Pharmaceuticals Inc at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Mascoma Wealth Management LLC | 5,000 | $24.0K | 0.01% |
| Tower Research Capital LLC (TRC) | 67 | $0 | 0.00% |
Sold out (6)
Institutions that held Merrimack Pharmaceuticals Inc at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Susquehanna International Group, LLP | 41,822 | $267.0K |
| Marshall Wace, LLP | 39,150 | $250.0K |
| Millennium Management LLC | 11,187 | $71.0K |
| Price T Rowe Associates Inc | 10,500 | $67.0K |
| JPMorgan Chase & Co | 525 | $3.00K |
| Cubist Systematic Strategies, LLC | 328 | $2.00K |